San Antonio—The combination of the PI3K inhibitor buparlisib and endocrine therapy with fulvestrant improved progression-free survival (PFS) in postmenopausal women with hormone receptor–positive/HER2-negative advanced breast cancer compared with fulvestrant alone, according to data from the BELLE-3 trial presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
The benefit, however, appeared to be confined to PIK3CA-mutant tumors, whether assessed at the primary site or in